Candel Therapeutics (US.CADL)
资本配置审计 · 期间： 2019 – 2026
核心指标
US.CADL · 同比： 2026 Q1 vs 2025 Q1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 103.7% | → |
| ROE | -6.4% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.36 | ↓ |
| Gross Margin | - | → |
US.CADL (Candel Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 103.7% → ROE -6.4% ↓ Cash Conversion - → D/E Ratio 0.36 ↓ Gross Margin - →
核心指标
US.CADL (Candel Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 103.7% →ROE -6.4% ↓Cash Conversion - →D/E Ratio 0.36 ↓Gross Margin - →免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies